Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations

Dean-Yar Tigrani; Jamie Weydert
April 2007
American Journal of Clinical Pathology;Apr2007, Vol. 127 Issue 4, p580
Academic Journal
The morphologic distinction of epithelioid mesothelioma from a reactive mesothelial proliferation can be difficult. Recent studies have demonstrated that serum osteopontin levels are increased in patients with mesotheliomas. We sought to determine if osteopontin expression is diagnostically helpful in distinguishing epithelioid mesothelioma from reactive mesothelial proliferations. We studied 7 cases of epithelioid mesothelioma and 20 cases of reactive mesothelial proliferations by immunohistochemical analysis using standard technique. All 7 mesotheliomas and 19 of 20 reactive mesothelial proliferations showed osteopontin expression.Osteopontin expression is not restricted to malignant mesothelial proliferations, and immunohistochemical analysis for osteopontin is not helpful in determining reactive vs malignant mesothelial proliferations. The reported usefulness of osteopontin as a serum tumor marker for mesothelioma may be due to differences in the amount or character of secreted protein in malignant mesothelioma compared with reactive mesothelial proliferations.


Related Articles

  • AKT answer relating to tumour markers.  // InnovAiT;Nov2009, Vol. 2 Issue 11, p693 

    The answer to an applied knowledge test on tumour markers is presented.

  • AKT question relating to tumour markers. Nandakumar, Michael // InnovAiT;Nov2009, Vol. 2 Issue 11, p673 

    The article presents an applied knowledge test on tumor markers.

  • Biomarkers for Malignant Pleural Mesothelioma. Greillier, Laurent; Baas, Paul; Welch, John J.; Hasan, Baktiar; Passioukov, Alexandre // Molecular Diagnosis & Therapy;Nov2008, Vol. 12 Issue 6, p375 

    Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose main etiology is exposure to asbestos fibers. The incidence of MPM is anticipated to increase worldwide during the first half of this century. For various reasons, MPM is difficult to diagnose and is...

  • Sigma-2 receptors as a biomarker of proliferation in solid tumours. Wheeler, K T; Wang, L-M; Wallen, C A; Childers, S R; Cline, J M; Keng, P C; Mach, R H // British Journal of Cancer;3/15/2000, Vol. 82 Issue 6, p1223 

    Over the past several years, our group has provided considerable evidence that the expression of sigma-2 (sigma2) receptors may serve as a biomarker of tumour cell proliferation. In these in vitro studies, sigma2 receptors were expressed 8-10 times more in proliferative (P) tumour cells than in...

  • Malignant mesothelioma of the tunica vaginalis. Abdelrahman, M; Dowling, CM; O’Connor, K; Mayer, N; Kiely, E // Journal of Surgical Case Reports;May2012, Vol. 2012 Issue 5, p2 

    Malignant mesothelioma of the tunica vaginalis is a rare but potentially fatal disease. Lack of characteristic clinical features and tumour markers makes the pre-operative diagnosis very difficult. A 54 year-old man with no history of exposure to asbestos presented with a short history of...

  • Clinical applications of tumor markers. Bast, Robert; Fenoglio-Preiser, Cecilia M.; Ozer, Howard; Sidransky, David; Glaser, Vicki // Patient Care;3/30/1993, Vol. 27 Issue 6, p61 

    Discusses several kinds of tumor markers and their clinical applications. Clinical tumor markers; Serum tumor markers; Cytogenetic markers.

  • Značaj praćenja serumskih tumorskih markera kod metastatskih karcinoma nepoznatog primarnog ishodiÅ¡ta. Pejčić, Ivica; Vrbić, Svetislav; Filipović, Sladjana; Šćekić, Mirjana; Petković, Ivan; Pejčić, Ljiljana; Djenić, Nebojša // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Sep2010, Vol. 67 Issue 9, p723 

    Background/Aim. Unknown primary tumors represent a heterogeneous group of malignancies that are indicative of ominous prognosis. Cancer of unknown primary site (CUP) is defined as the lack of any detectable primary site after full evaluation, and accounts for approximately 3-5% of all newly...

  • Tumour markers: their use and misuse by clinicians. McGinley, Peter J; Kilpatrick, Eric S // Annals of Clinical Biochemistry;Nov2003, Vol. 40 Issue 6, p643 

    Background: Several guidelines exist on the appropriate use of serum tumour markers in the management of patients with cancer. This study audited tumour marker requesting against these guidelines in a busy teaching hospital over a 12-month period. Methods: All marker requests from 1 April 2001...

  • Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). McShane, Lisa M.; Altman, Douglas G.; Sauerbrei, Willi; Taube, Sheila E.; Gion, Massimo; Clark, Gary M. // JNCI: Journal of the National Cancer Institute;8/17/2005, Vol. 97 Issue 16, p1180 

    Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics